Objective: To investigate the molecular pathway of the cytotoxic effect of SN-38 in human cervical cancer cell lines.
Introduction
Carcinoma of the cervix is the second most common neoplasm in Indonesian women and the second most common neoplasm leading to female cancer mortality. 1 Furthermore, it is also the second most frequently found cancer among women in reproductive age between 15-44 years old. 2 It constitutes almost 15,000 new cases and 7,500 deaths per annum. 2 Cervical cancer treatment depends on the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging. Early stadium of cervical cancer is generally treated with radical operations but up to now there is no fixed standard therapy for FIGO stadium Ib-IIa of cervical cancer. Cancer within these stadiums can be treated with radical operation, radiotherapy, surgery-radiotherapy combination, surgeryanticancer drug combination, or chemotherapy although these combination therapy protocols may vary. The administration of the combination therapy for each patient is based on many factors including age, general condition, and patient's preference to achieve maximum therapy target with minimum complications.
The standard surgery for cervical cancer in stadium Ib and IIa is radical hysterectomy with pelvic lymphadenectomy. The benefit of surgical therapy is the ability to extract primary tumor and apply staging accurately which leads to the selection of the most appropriate type of adjuvant therapy for the patient. For stadium Ib2 and IIa, neoadjuvant chemotherapy is one of several adjuvant therapy alternatives applied. The goal of this neoadjuvant chemotherapy is to eradicate micrometastasis and reduce primary tumor volume so the next treatment effectiveness can be improved both for surgery and radiotherapy. In addition to radiotherapy, chemotherapy is the standard treatment for advanced cervical cancers. However, the systemic therapy protocol for this kind of cervical cancer keeps changing. In the past, chemotherapy was used for recurrent and persistent cervical cancer, or cervical cancers with metastasis. Currently, chemotherapy is the primary treatment for cervical cancers with a high risk of reccurrency.
The best possible treatment of locally advanced cervical cancer is a combination of radiation and cisplatin-based chemotherapy. Cisplatin-based chemotherapy as the main regimen is still the primary choice for advanced, metastatic, and recurrent cervical cancers. Even with this regimen, the response rate of advanced stadium patients was only 23% with limited response time. 3 From this data, it is suggested that conventional treatment methods have reached a plateau and, therefore, to overcome this problem, finding a good prognostic factor and predictor response to chemotherapy might be useful.
Irinotecan (CPT-11) and its analog have given promising results on many clinical trials. SN-38, which is a semi-synthetic derivative of camptothecin, is the active metabolite of Irinotecan. Like other camptothecin-derivatives, SN-38 inhibits topoisomerase I (Topo I), a nuclear enzyme needed for replication and transcription by unwinding supercoiled DNA. 4 SN-38 interferes with Topo I activity by trapping Topo I-DNA cleavage complexes, leading to lethal replication-mediated double strand breaks and ended with cell death. 4 Currently, irinotecan is used as a standard therapy for colon cancer but not for cervical cancer. Irinotecan specificity against cervical cancer needs to be studied.
Chemotherapeutic agents kill cancer cells through interaction with several distinct intracellular targets, including factors affecting cells cycles, apoptosis cell death, and survival pathways. Class I phosphatidylinositol 3-kinase (PI3K) and its downstream effectors, such as Akt and mTOR, have emerged as a prominent proliferation and survival pathway. Activation of the PI3K/Akt-mTOR pathway has been implicated in many human cancers and shown to be associated with chemoresistance. 5 We have previously shown that advanced cervical cancer expressed Akt and mTOR and the expression of p-mTOR could predict the response to neoadjuvants and the survival of the patients treated with cisplatin-based neoadjuvant chemotherapy. 6, 7 A therapeutic strategy for selectively modulating the expression of a gene of interest is the use of inhibitor agents of Akt such as LY294002 and inhibitor agents of mTOR such as rapamycin. We assessed whether the active form of irinotecan treatment enhanced the inhibition of proliferation signals, in this case the Akt-mTOR pathway, which led to increase of cell death. Drugs and cell treatment Irinotecan was purchased from Wako Pure Chemicals (Osaka, Japan) and received as sterile lyophilized powder. A stock solution of 5 mg/ mL was made in dimethylsulfoxide (DMSO) and stored at 4 °C. Further dilutions were made in culture media to reach the desired concentrations when the cells obtained approximately 80% confluency. The final concentration of DMSO did not exceed 0.08%, a concentration that does not alter the growth or survival properties of any cell type. We used CPT-11 and SN-38 stock of 3 μM peak plasma concentration (ppc) with a range of 9.8 ng/mL-5 μM. LY294002 and rapamycin were purchased from Calbiochem (San Diego, CA). For LY294002 (25 μM) or rapamycin (100 nm), cells were pre-incubated with these inhibitors for 6 hours (h) prior to irinotecan treatment.
Methods
Drug sensitivity assay Cell proliferation analysis was performed on human cervical cancer cell lines in the presence of various concentrations of drugs by a colorimetric
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Chemosensitivity to Active form of Irinotecan (SN-38) methyl thiazolyl tetrazolium (MTT) assay. Briefly, exponentially growing cells (2x104 cells/well) were plated in 96-well plates. After an overnight culture, the medium was substituted by a fresh medium with different concentrations of drugs. At the end of various treatments, 10 μL of a cellcounting solution (WST-8, Dojindo Labs, Tokyo, Japan) was added. After dissolving the crystals with 1 N HCl-isopropanol, the absorbance was measured at a wavelength of 450 nm using a microtiter plate reader (Beckton Dickinson, Franklin Lakes, NJ). A value of 100% was assigned to untreated control and the concentration of drug that reduced the number of viable cells to 50% after 24 h of exposure (CPI 50 ) was derived from cell survival plots. All experiments were performed in triplicate.
Light microscopy examination All cells were cultured in a 6-cm plate and treated with drugs as described previously. Morphological changes were examined at the times indicated and photographed using a regular phase contrast microscope.
Western blot analysis Western blot analysis was applied as described. 5 Cells were harvested at the time indicated and prepared in a buffer (20 mM Tris-HCl, pH 7.6, 1 mM EDTA, 140 mM NaCl, 1% Nonidet P-40, 1% aprotinin, 1 mM phenylmethylsulfonylfluoride, and 1 mM sodium vanadate). 
Results

Sensitivity of human cervical cancer cells to CPT-11 and SN-38
To investigate the sensitivity of human cervical cancer cells to CPT-11 and SN-38, the cells were treated for 24-72 h in a medium containing various concentrations of drugs. The exposure to drugs (9,8 ng/mL-5 μM) produced a dose and time dependent cell growth reduction in HeLa and CaSki cells ( Fig. 1-2 8 It was recently reported that Akt plays an important role in determining the chemosensitivity of many kinds of cells. [9] [10] [11] We evaluated the expression of these survival signaling proteins in response to SN-38 exposure in cervical cancer cells. It showed that SN-38 inhibited the activation of Akt in CaSki cells in dose and time dependent manner as shown by the reduced expression of active form or phosphorylated Akt (Ser473; 60 kDa), phosphorylated mTOR (Ser2448; 289 kDa) and phosphorylated p70 S6 Kinase (Thr389; 70 kDa) (Fig. 4) . On the other hand, for HeLa cells, there is not much modification of the active form Akt (p-Akt), mTOR (p-mTOR) and pS6K1 expression. These results indicate that SN-38 downregulated differently in both cervical cancer cells. CaSki cells are more sensitive to SN-38 treatment compared to HeLa cells. These results indicate that the Akt-mTOR pathway Inhibition of Akt-mTOR pathway increases the sensitivity of SN-38 induced apoptosis To confirm whether the Akt-mTOR pathway plays a role in response to SN-38, the LY294002 and rapamycin as pretreatment to irinotecan were used. Pre-treatment with LY294002 and rapamycin significantly enhance the cell proliferation inhibition in HeLa cells (p<0.05, Table 2 pre-treatment with rapamycin significantly enhanced the chemosensitivity of CaSki cells to SN-38 (p<0.05, Table 2 ). To further evaluate the effect of pre-treatment with these inhibitor agents on apoptosis, an analysis on the morphological changes were performed using phase contrast microscopy. The results show that pre-treatment with rapamycin induced apoptosis in most of CaSki cells, which appeared as bright, rounded, and detached cells from the dish.
Discussion
Irinotecan, which is one of the anti-neoplastic agents with the broadest spectrum, is currently used in the treatment of many types of advanced cancers, but not in the cervical carcinoma. Until now, the prognosis of patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix has been poor. 1, 2 Resistance to chemotherapy is the most frequent obstacle to effective treatment. Although the molecular mechanisms of paclitaxel in the mediation of cell death are well characterised, its effects on survival signaling remain unclear. This study determined the sensitivity of human cervical cancer cells to irinotecan (CPT-11) as well as its active form (SN-38) and the results from the MTT assay showed that CaSki cells had the highest sensitivity, whereas HeLa cells was the most resistant. Furthermore, an examination on whether CPT-11 and SN-38 induced apoptosis in human cervical cancer cells was also performed. To determine the molecular mechanism that mediates the cytotoxic effect of SN-38 in human cervical cancer cells, we performed Western blot analysis. In this study, it is demonstrated that SN-38 activated caspase-8, caspase-9, caspase-3 and PARP in CaSki cells. These results indicate that in sensitive CaSki cells the induction of apoptosis by SN-38 might take place through intrinsic and extrinsic pathways.
It was recently reported that CPT-11 and SN-38 activate a serine/threonin protein kinase Akt, which is the downstream target of PI3K. 10, 12 Our results demonstrated that SN-38 inhibits the activation of Akt in CaSki cells, which were more suggestive of a sensitive phenotype, which is shown by the downregulation of phosphorylated Akt at serine 473, phosphorylated mTOR at Ser2448, and phosphorylated p70 S6 Kinase at Thr389. Akt-mTOR pathways have the main role in promoting cell survival and are frequently associated with chemoresistance to cytotoxic drugs. The elevation level of phosphorylated Akt-mTOR pathways was reported to be involved in the mechanism of chemoresistance. there was no altered activation of Akt-mTOR pathways to SN-38 treatment. It is tempting to speculate that the Akt-mTOR inhibitor might have an important role in promoting the cell death of HeLa cells. To elucidate this phenomenon, we have conducted experiments using LY294002 or rapamycin as the Akt-mTOR inhibitor. We observed that the inhibition of Akt activation using LY294002 significantly enhance the sensitivity to SN-38 in HeLa cells (p<0.05). Furthermore, the inhibition of mTOR activation using rapamycin more significantly enhance the sensitivity to SN-38 in HeLa cells (p<0.01). Rapamycin has been found to inhibit serine/threonin kinase mTOR by binding to the immunophilin FK506-binding protein 12 (FKBP12). The inhibition of mTOR kinase leads to dephosphorylation of its two major downstream signaling components, p70 S6 kinase (S6K1) and 4E-BP1.
14 Furthermore, we used rapamycin to inhibit Akt-mTOR activation in both HeLa and CaSki cells. As expected, we found that the inhibition of Akt-mTOR significantly enhanced the sensitivity of HeLa cells to irinotecan. Analysis of the morphology of cells under lightmicroscopy strengthened our findings that the inhibition of Akt-mTOR effectively increased irinotecan-induced apoptosis. Taken together, our results suggest that Akt-mTOR and its downstream effectors, S6K1, play a role in the survival of HeLa cells and that the inhibition of mTOR signaling may substantially potentiate apoptosis.
In summary, the study presented here is the first to directly address the potential of targeting Akt-mTOR protein in the enhancement of therapeutic efficacy of a Topoisomerase I agent, irinotecan, in human cervical cancer cell lines. This information may increase our understanding to apply molecular targeting therapies that may improve the management of cancer with chemotherapy.
